Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. released partial results from their first of three exenatide Phase III trials in Type II diabetes, disclosing enough information to show the product hit its primary endpoint and to raise Amylin's stock. (BioWorld Today)
Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. released partial results from their first of three exenatide Phase III trials in Type II diabetes, disclosing enough information to show the product hit its primary endpoint and to raise Amylin's stock. (BioWorld Today)
Genzyme Corp., Biogen Inc. and Abbott Bioresearch Center filed suit earlier this summer against Columbia University in the U.S. District Court of Massachusetts, claiming that a new patent issued to the university in September 2002 that centered on cotransformation technology was "invalid and unenforceable." (BioWorld Financial Watch)
Genzyme Corp., Biogen Inc. and Abbott Bioresearch Center filed suit earlier this summer against Columbia University in the U.S. District Court of Massachusetts, claiming that a new patent issued to the university in September 2002 that centered on cotransformation technology was "invalid and unenforceable." (BioWorld Financial Watch)
